Day 1 - Tuesday 29th April 2025
12th Market Access, Pricing & Reimbursement Global Congress 2025 Europe
Comprehensive Strategies and Embracing Innovations to Overcome Barriers in Patient Access
Copthorne Tara Hotel London Kensington, London, UK
Robert Mitchell-Thain, CEO, PBC Foundation
MARKET ACCESS TRENDS & STRATEGIES
- Navigating complex requirements to achieve and maintain market access in the EU and globally
- Addressing varying market access and payer models to accelerate patient access to treatment
- Integrating evidence development with market access strategy
- Creating a robust clinical evidence for HTA assessment
- Tackling the challenges on drug affordability
Moderator:
Panelist:
Nazanin Mehin, Head of Global Market Access and Pricing for Immunology, Sanofi
- Impact of recent changes on companies that decide to invest in the EU, with consequences that will also affect market access in Member States, patients, healthcare systems and EU competitiveness.
- Recommendations on how to ensure efficient and effective implementation of the JCA at the national level
- Identify metrics that will enable iterative learning among stakeholders.
- Future considerations for involvement in JCA and national implementation at the Member State level.
- The need for better access to quality data
- Expanding clinical research
- Scaling up manufacturing of advance therapies
- Creating spending decisions that aligns with healthcare priorities
- Building a globally competitive ecosystem
- Why and how enterprises should invest into early HEOR and pathway improvement?
- How AI can impact early HEOR and pathway improvement evaluations: key benefits to the life sciences and medtech industry
- Case examples from the UK
- When and how to integrate value planning into development
- Staying responsive to changing market conditions
- Trends to watch
- Enabling diverse perspectives through timely engagement
RESERVED
- Addressing the factors that made the launch environment more challenging
- Capabilities needed for an effective drug launch
- How to best leverage outsourced partners to achieve success.
- Best practices to achieve successful commercialisation
- As interventional technologies gallop forward, payers react by evolving their methodologies for assessing effectiveness and willingness to reimburse. As we plan clinical development, we must strategise to ensure the best investment for patients, businesses, and the healthcare market. Accurate accounting for
market access opportunities and challenges is critical across the pre-launch and post-launch timeline.
This presentation will focus on how the pharmaceutical multidisciplinary team must work together to ensure the healthcare system can treat patients in a timely and effective way.
Alison Lawrence, Associate Principal, Decisive Consulting Ltd
To Follow shortly
Nazanin Mehin, Head of Global Market Access and Pricing for Immunology, Sanofi
- Rare Diseases landscape
- Acquisition Trends
- High failure rate
- De-risking challenges
- Identifiable Factors Contribute to Risk
- Re-Defining Success
- Challenges and obstacles in bringing this highly complex therapies to market
- Lessons learned and applications for new entrants
- Strategies that can be taken to improve timely market access and access for patients
- Innovative contracting for cell & gene therapies in the EU
- Stakeholder collaboration on the road towards a solution
- Understanding and including the patients’ perspectives in designing clinical trials and clinical endpoint
- Key principles that ensure access to treatment based on need
- Patient-centeredness, patient advocacy
- Looking beyond market access to patient access
- What patients can bring to access and how to support them
- Collaborating for success in access
Josie Godfrey, Co-Founder and CEO, Realise Advocacy
Lindsay Birrell, Co- CEO, Realise Advocacy, Chair of trustees, Medics 4 Rare Diseases
- Access to innovative medicines remains a key issue worldwide
- Identifying the root cause of inequitable access
- Limitations of the some of the initiatives to address this such as the EUnetHTA JCA and the changes in legislation in Europe
- Developing solutions that are sustainable and scalable
- How can pharmaceutical companies and health authorities work together to bridge the gap
Moderator:
Panellist:
Zavy Gabriel, Head of International Market Access, AstraZeneca
